Shares of Novavax Inc. NVAX slid 3.09% to $7.83 Wednesday, on what proved to be an all-around mixed trading session for the ...

Novavax Inc. closed 66.14% below its 52-week high of $23.86, which the company reached on June 6th.

In the closing of the recent trading day, Novavax (NVAX) stood at $8.19, denoting a +0.74% change from the preceding trading day.

According to the 6 industry analysts covering Novavax, the consensus is that breakeven is near. They anticipate the company to incur a final loss in 2024, before generating positive profits of US$82m ...

Spire Wealth Management bought a new position in Novavax, Inc. (NASDAQ:NVAX – Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange ...

Vaccines are powerful tools that can help those living in nursing homes avoid or curtail common seasonal infections, such as the flu, RSV, COVID-19 and pneumonia.

Novavax (NVAX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

Bank of America Securities analyst Alec Stranahan reiterated a Hold rating on Novavax (NVAX – Research Report) today and set a price target of ...

Faced with the encroaching threats of patent expirations and generics, biopharma companies in 2024 invested 33% more in ...

Dynavax should take a leaf from its vaccine maker peer, Novavax, and work to monetize its CpG1018 adjuvant. Learn more about ...